Pfizer held its Q1 2026 earnings conference call on May 5, 2026, with chief scientific officer Chris Boshoff signaling that the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) had met its primary endpoint and that two pivotal oncology readouts — for sigtolimod vedotin in non-small cell lung cancer (NSCLC) and mevrometostat in prostate cancer — remain on track for mid-to-late 2026. The Pfizer first quarter 2026 results also marked the first public disclosure of a 35-valent fifth-generation adult pneumococcal vaccine candidate entering clinical development this year.
Key Strategic Signals
Elrexfio / MagnetisMM-5: Pfizer announced positive top-line results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) the week before the call, with the bispecific antibody showing statistically significant improvement in progression-free survival in double-class exposed patients with relapsed or refractory multiple myeloma who had received at least one prior line of treatment. CEO Albert Bourla framed this as a move toward reaching patients earlier in their disease course, representing a potential label expansion beyond the drug's current positioning in heavily pretreated disease.
Atirmociclib — CDK4 inhibitor acceleration: Pfizer presented randomized Phase II data for atirmociclib, its potential first-in-class selective CDK4 inhibitor, in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer who had received prior CDK4/6 inhibitor-based treatment. Management said the data suggested differentiated efficacy and tolerability relative to the CDK4/6 inhibitor class and stated the company intends to accelerate development into first-line and early breast cancer settings, explicitly framing atirmociclib as a potential next-generation backbone therapy. The Albert Bourla earnings call remarks positioned this program as central to Pfizer's long-term breast cancer franchise strategy.
Metsera obesity portfolio — ADA as near-term inflection point: Pfizer said it intends to advance 10 Phase III studies this year from its Metsera-acquired obesity portfolio, targeting a first approval in 2028. Boshoff confirmed that detailed data from VESPER-3, open-label extension data from VESPER-1, and data from VESPER-2 — evaluating weekly danuglipron with or without titration in participants with type 2 diabetes — will all be presented at the upcoming American Diabetes Association meeting. Data on an amylin monotherapy candidate and an amylin/GLP-1 combination, covering 24-week and 28-week readouts respectively, are expected in the second half of 2026 and will not be shared at ADA.
Next-generation pneumococcal vaccines — dual-track strategy disclosed: Pfizer initiated a Phase III program for a 25-valent pediatric pneumococcal conjugate vaccine candidate the day before the call, incorporating increased valency and next-generation serotype 3 technology. Separately, Bourla disclosed for the first time that Pfizer has decided to advance directly to a fifth-generation adult vaccine candidate covering 35 serotypes, with clinical development entry expected in 2026. Management said this approach was chosen to maintain market leadership in the adult segment over the long term.
Analyst Pressure Points
Sigtolimod vedotin — evidentiary basis for pivotal readout: Analyst Courtney Breen pressed Boshoff on how the planned first-line all-comers Phase III study for sigtolimod vedotin (SV) is positioned relative to the already-enrolling Symbiotic-Lung-01 study and a Phase I/II combination study. Boshoff acknowledged that the efficacy signal underpinning the second-line Phase III versus docetaxel — which is expected to read out around mid-2026 and is powered for overall survival — rests on a single-arm Phase I experience with a median overall survival of approximately 16.3 months. He also noted that the first-line pembrolizumab combination data in programmed death-ligand 1 (PD-L1)-high patients came from a small cohort, though he said every patient in that population responded. The second-line study is restricted to non-squamous histology based on signals observed in earlier-stage data.
Growth bridge to 2029 — pipeline risk adjustment: Goldman Sachs analyst Asad Haider questioned how Pfizer intends to bridge the gap between current loss-of-exclusivity (LOE) headwinds and the targeted high single-digit five-year revenue compound annual growth rate beginning in 2029. Bourla said the pipeline contributions embedded in that projection are heavily risk-adjusted across a large number of assets, and that the recent Vyndamax (tafamidis) patent settlement — which extends exclusivity to mid-2031 and protects a product generating more than USD 6 billion annually — reduces the effective LOE exposure from approximately USD 17 billion to USD 14 billion to USD 15 billion. He said statistical diversification across multiple pipeline assets underpins confidence in the aggregate projection.